进入创新通道！经导管植入式无导线心脏起搏器

Company Overview - Dunbo Medical, established in 2018 and headquartered in Xi'an, Shaanxi Province, is a high-tech company focused on the research and production of Class III active implantable medical devices [26] - The company has developed key medical and semiconductor technologies, including proprietary mixed-signal chips, hardware circuits, software applications, and structural materials [26] - Dunbo Medical has completed four rounds of financing to support its growth and product development [26] Product Highlights - Dunbo Medical's core product is a leadless cardiac pacemaker, which integrates the pulse generator and pacing electrode into a compact capsule that can be directly implanted into the heart [12][14] - The leadless pacemaker has advantages such as a smaller size (only 0.8cc), ease of use, and enhanced safety, eliminating risks associated with lead damage and pocket infections [10][14] - The product's design allows for a significant reduction in complications compared to traditional pacemakers, which rely on leads that can cause infections and displacements [8][10] Market Context - The prevalence of heart failure in China is increasing, with approximately 13.7 million patients aged 35 and older, and an annual increase of around 3 million new cases [15] - The cardiac pacemaker market in China is projected to reach 6.8 billion yuan by 2024, with imported products holding a market share of 89%, indicating a significant opportunity for domestic alternatives [15] - Despite the absence of successful domestic CRT products, there have been notable advancements in other innovative devices for heart failure treatment, such as left ventricular assist devices and cardiac contractility modulation devices [15][16][24] Innovations in Heart Failure Treatment - The left ventricular assist device (LVAD) market is maturing, with four domestic systems approved for sale, each offering unique market advantages [16] - The D-shant atrial shunt device has entered the "national innovative medical device" green channel and is undergoing clinical trials, positioning it competitively against international players [22][23] - The cardiac contractility modulation (CCM) device, developed by Lepu Medical, has passed the special review application and is expected to receive approval soon, marking a significant milestone for domestic innovation in heart failure treatment [24]